EndolucinBeta contains the radioactive compound lutetium (177Lu) chloride and is used for radiolabelling other medicines. Radiolabelling is a technique for tagging (or labelling) medicines with radioactive compounds so they can carry radioactivity to where it is needed in the body, for example the site of a tumour. EndolucinBeta isl to be used to radiolabel medicines that have been specifically developed for use with lutetium (177Lu) chloride.
Therapeutic Indication
EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.
Therapeutic Area (MeSH)
ATC Code
V10X
ATC Item
N/A
Pharmacotherapeutic Group
Therapeutic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| lutetium (177Lu) chloride | N/A | lutetium (177Lu) chloride |
EMA Name
EndolucinBeta
Medicine Name
EndolucinBeta
Aliases
N/ANo risk management plan link.
